ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
118.532,68
-1,33%
S&P 500
5.942,47
1,26%
US Dollar vs BRL
6,1822
0,00%
Bitcoin
97.726,97
-0,39%
Brent Oil
76,495
0,00%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Incannex Healthcare Ltd (IXHL)

  7. Incannex Healthcare Ltd (IXHL) Notícias

IXHL

Incannex Healthcare (IXHL)

Incannex Healthcare Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IXHL
DataHoraFonteTítuloCódigoCompanhia
11/12/202418:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
09/12/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IXHLIncannex Healthcare Ltd
06/12/202418:23Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IXHLIncannex Healthcare Ltd
26/11/202418:06Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IXHLIncannex Healthcare Ltd
14/11/202418:05GlobeNewswire Inc.Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business UpdatesNASDAQ:IXHLIncannex Healthcare Ltd
12/11/202408:07Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:IXHLIncannex Healthcare Ltd
12/11/202408:04Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:IXHLIncannex Healthcare Ltd
06/11/202418:19Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IXHLIncannex Healthcare Ltd
31/10/202417:10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IXHLIncannex Healthcare Ltd
24/10/202417:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
24/10/202417:48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
24/10/202408:30GlobeNewswire Inc.Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical OfficerNASDAQ:IXHLIncannex Healthcare Ltd
30/09/202417:01GlobeNewswire Inc.Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business UpdatesNASDAQ:IXHLIncannex Healthcare Ltd
30/09/202408:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IXHLIncannex Healthcare Ltd
10/09/202409:00GlobeNewswire Inc.Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena InvestorsNASDAQ:IXHLIncannex Healthcare Ltd
10/09/202408:00Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:IXHLIncannex Healthcare Ltd
05/08/202408:30GlobeNewswire Inc.FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to ProceedNASDAQ:IXHLIncannex Healthcare Ltd
30/07/202408:30GlobeNewswire Inc.Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42XNASDAQ:IXHLIncannex Healthcare Ltd
30/05/202408:30GlobeNewswire Inc.Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep ApneaNASDAQ:IXHLIncannex Healthcare Ltd
07/05/202408:30GlobeNewswire Inc.Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorderNASDAQ:IXHLIncannex Healthcare Ltd
16/04/202409:00GlobeNewswire Inc.Incannex Healthcare Inc. Quarterly Update, Q1 2024NASDAQ:IXHLIncannex Healthcare Ltd
28/02/202409:30GlobeNewswire Inc.Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety DisorderNASDAQ:IXHLIncannex Healthcare Ltd
16/02/202409:30GlobeNewswire Inc.Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking CessationNASDAQ:IXHLIncannex Healthcare Ltd
14/02/202408:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IXHLIncannex Healthcare Ltd
01/02/202409:30GlobeNewswire Inc.Clarion Clinics Open for Psychedelic-Assisted TreatmentsNASDAQ:IXHLIncannex Healthcare Ltd
24/01/202418:05GlobeNewswire Inc.Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid ArthritisNASDAQ:IXHLIncannex Healthcare Ltd
18/01/202410:22GlobeNewswire Inc.Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis CommencesNASDAQ:IXHLIncannex Healthcare Ltd
17/01/202409:30GlobeNewswire Inc.Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep ApneaNASDAQ:IXHLIncannex Healthcare Ltd
21/12/202318:05GlobeNewswire Inc.Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in AustraliaNASDAQ:IXHLIncannex Healthcare Ltd
20/12/202319:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IXHLIncannex Healthcare Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:IXHL

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
USIM5
USIMINAS PNA
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
BRSR6
BANRISUL PNB
BOV
INBR32
Inter &
BOV
GFSA3
GAFISA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados